Evidence map›Paper›PMID 42266765›Full record

ArticleClinical, cosmetic and investigational dermatology2026

Subtype-Specific Response to Fractional-Mode Q-Switched Ruby Laser in Melasma: A Prospective Single-Blind Clinical Study Using Clinical and Noninvasive Imaging Assessments.

Yulan Wang, Zongxiang Li, Zhichao Wen, Jia Liu, Zhenhang Li

Abstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yulan WangDepartment of Dermatology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Zongxiang LiDepartment of Dermatology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Zhichao WenDepartment of Dermatology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Jia LiuDepartment of Dermatology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Zhenhang LiDepartment of Dermatology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Melasma is a chronic relapsing facial hyperpigmentation disorder with pigmentary and vascular heterogeneity. This study compared responses of pigmentary melasma (M), characterized predominantly by brown hyperpigmented macules or patches with non-dominant vascularity, and pigmentary-vascular melasma (M+V), characterized by pigmentation with persistent erythema or telangiectatic vascular features, to fractional-mode 694 nm Q-switched ruby laser. Methods: In this prospective, single-center, single-blind clinical study with assessor-blinded outcome evaluation, 100 women with facial melasma were classified at baseline as M (n = 50) or M+V (n = 50) by clinical examination and dermoscopy. All received three laser sessions at 4-week intervals. Outcomes included MASI, VISIA brown spots, ultraviolet spots, red areas, dermoscopic vascular scores, responder status, patient-reported improvement, satisfaction, and adverse events. Results: Ninety patients completed week 12 assessment (M, n = 42; M+V, n = 48). Week 12 MASI percentage reduction was 71.1% ± 13.5% in M versus 51.2% ± 12.3% in M+V ( Conclusion: Fractional-mode 694 nm Q-switched ruby laser improved both subtypes, but pigmentary melasma showed a more favorable response. Baseline clinicodermoscopic subtype classification and multimodal assessment may support individualized laser treatment and response evaluation.

Indexed as

dermoscopylaserslaser therapymelasmaprospective studiessolid-statetreatment outcome

Identifiers

PMID42266765
PMCPMC13245443

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.